McKesson may take over fellow distributor Celesio; Baxter nabs FDA approval for IV supplement;

@FiercePharma: Trending this a.m. online: Forget drug-sales forecasts, study finds. They're usually wrong. Who does it best? Article | Follow @FiercePharma

@CarlyHFierce: From FierceVaccines: GlaxoSmithKline targeting a 2015 launch for its malaria vaccine. Report | Follow @CarlyHFierce

> German drug distributor Celesio's shares leapt after media reported a potential takeover by U.S.-based McKesson ($MCK). Report

> Baxter Healthcare ($BAX) won FDA approval for Clinolipid, an intravenous nutritional supplement, after a priority review to help alleviate a drug shortage. Report

> PhRMA says it will set up a Middle East and Africa regional office at DuBiotech, a free zone in Dubai, UAE. Report

> A U.S. District judge delayed the planned transfer of hundreds of lawsuits over injuries allegedly caused by Merck's ($MRK) bone drug Fosamax to allow more time for settlement talks. Report

> China's CONBA Pharma said its profits so far this year are up about 70%. Report

> Doctors continue to overprescribe antibiotics, especially to patients with a sore throat or bronchitis, which usually can't be treated with bacteria-fighting drugs. Report

> Texas officials refused to return execution drugs to a compounding pharmacy that wants them back. Report

Medical Device News

@FierceMedDev: New special report: Med tech's hottest takeover targets for the rest of 2013. Feature | Follow @FierceMedDev

@MarkHFierce: Quest Diagnostics is expanding through a Peabody, MA acquisition (My old professional stomping grounds.) News | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Alnylam posts positive PhI for RNAi cholesterol drug. Story from FierceDrugDelivery | Follow @MichaelGFierce

> ProTip's artificial larynx successfully implanted in male patient. More

> Tandem seeks $100M IPO amid burgeoning market. Story

> Biomet buying Lanx with eye on spinal implants. News

Biotech News

@FierceBiotech: Special Report: 10 top drugs in biopharma's late-stage pipeline. Feature | Follow @FierceBiotech

@JohnCFierce: Want to buy a million-square-foot monument to Merck's past glory? More | Follow @JohnCFierce

@DamianFierce: The FDA outlines its shutdown activities--nothing that hasn't been reported, but a handy document no less. More | Follow @DamianFierce

> Post-restructuring, Pfizer R&D focused on its top blockbuster prospects. More

> J&J snaps up an NS5A inhibitor from GlaxoSmithKline for hep C cocktail. News

> Versartis nabs $20M to take growth hormone to PhIII. Story

> Bayer spotlights its late-stage pipeline contenders in cancer, cardio. Article

Pharma Manufacturing News

@EricPFierce: Projecting $140M annual operating losses, Boehringer says Ben Venue plant not worth keeping open. Story | Follow @EricPFierce

> Aesica fined $161,000 for worker injury. Report

> Sartorius picking up TAP Biosystems in $45M deal. Story

> Recipharm, Fujifilm expand their biologics capabilities. Article

> Ranbaxy may look to buy FDA-approved plant in India. Item

Biotech Research News

@EmilyMFierce: There's a Major Foodborne Illness Outbreak and the Government's Shut Down. More from Wired | Follow @EmilyMFierce

> Three U.S.-based scientists jointly win Nobel Prize for cell transport discoveries. Article

> $6.25M grant establishes leukemia research initiative. Item

> Yale team investigates promising new class of antidepressants. Story

> Chemical in red wine kills cancer cells even after it's metabolized. More

And Finally... A Swedish study found no evidence to support theories of a viral cause for breast cancer and a type of brain tumor. Release